195 related articles for article (PubMed ID: 23454352)
21. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
[TBL] [Abstract][Full Text] [Related]
22. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
Mittapalli RK; Vaidhyanathan S; Sane R; Elmquist WF
J Pharmacol Exp Ther; 2012 Jul; 342(1):33-40. PubMed ID: 22454535
[TBL] [Abstract][Full Text] [Related]
23. Impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of antiepileptic drugs in knockout mouse models.
Nakanishi H; Yonezawa A; Matsubara K; Yano I
Eur J Pharmacol; 2013 Jun; 710(1-3):20-8. PubMed ID: 23588114
[TBL] [Abstract][Full Text] [Related]
24. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
[TBL] [Abstract][Full Text] [Related]
25. Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice.
Agarwal S; Uchida Y; Mittapalli RK; Sane R; Terasaki T; Elmquist WF
Drug Metab Dispos; 2012 Jun; 40(6):1164-9. PubMed ID: 22401960
[TBL] [Abstract][Full Text] [Related]
26. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier.
Eisenblätter T; Hüwel S; Galla HJ
Brain Res; 2003 May; 971(2):221-31. PubMed ID: 12706238
[TBL] [Abstract][Full Text] [Related]
27. An electrically tight in vitro blood-brain barrier model displays net brain-to-blood efflux of substrates for the ABC transporters, P-gp, Bcrp and Mrp-1.
Helms HC; Hersom M; Kuhlmann LB; Badolo L; Nielsen CU; Brodin B
AAPS J; 2014 Sep; 16(5):1046-55. PubMed ID: 24934296
[TBL] [Abstract][Full Text] [Related]
28. Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats.
Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Löbsch M; Stanek J; Wanek T; Sake JA; Pekar T; Ehrhardt C; Langer O
J Control Release; 2022 Sep; 349():109-117. PubMed ID: 35798092
[TBL] [Abstract][Full Text] [Related]
29. Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.
Becker CM; Oberoi RK; McFarren SJ; Muldoon DM; Pafundi DH; Pokorny JL; Brinkmann DH; Ohlfest JR; Sarkaria JN; Largaespada DA; Elmquist WF
Neuro Oncol; 2015 Sep; 17(9):1210-9. PubMed ID: 25972455
[TBL] [Abstract][Full Text] [Related]
30. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
[TBL] [Abstract][Full Text] [Related]
31. Homozygous disruption of the mdrla P-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs.
Saito T; Zhang ZJ; Ohtsubo T; Noda I; Shibamori Y; Yamamoto T; Saito H
Acta Otolaryngol; 2001 Sep; 121(6):735-42. PubMed ID: 11678173
[TBL] [Abstract][Full Text] [Related]
32. Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
Wang T; Agarwal S; Elmquist WF
J Pharmacol Exp Ther; 2012 May; 341(2):386-95. PubMed ID: 22323823
[TBL] [Abstract][Full Text] [Related]
33. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin.
Chen WS; Luker KE; Dahlheimer JL; Pica CM; Luker GD; Piwnica-Worms D
Biochem Pharmacol; 2000 Aug; 60(3):413-26. PubMed ID: 10856437
[TBL] [Abstract][Full Text] [Related]
34. Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study.
Bankstahl JP; Bankstahl M; Römermann K; Wanek T; Stanek J; Windhorst AD; Fedrowitz M; Erker T; Müller M; Löscher W; Langer O; Kuntner C
Drug Metab Dispos; 2013 Apr; 41(4):754-62. PubMed ID: 23305710
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier.
Zhao R; Raub TJ; Sawada GA; Kasper SC; Bacon JA; Bridges AS; Pollack GM
Drug Metab Dispos; 2009 Jun; 37(6):1251-8. PubMed ID: 19273529
[TBL] [Abstract][Full Text] [Related]
36. Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice.
Geyer J; Gavrilova O; Petzinger E
J Vet Pharmacol Ther; 2009 Feb; 32(1):87-96. PubMed ID: 19161460
[TBL] [Abstract][Full Text] [Related]
37. [(18)F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier.
Wanek T; Traxl A; Bankstahl JP; Bankstahl M; Sauberer M; Langer O; Kuntner C
Nucl Med Biol; 2015 Jul; 42(7):585-9. PubMed ID: 25823393
[TBL] [Abstract][Full Text] [Related]
38. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
Agarwal S; Sane R; Ohlfest JR; Elmquist WF
J Pharmacol Exp Ther; 2011 Jan; 336(1):223-33. PubMed ID: 20952483
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate.
Mairinger S; Langer O; Kuntner C; Wanek T; Bankstahl JP; Bankstahl M; Stanek J; Dörner B; Bauer F; Baumgartner C; Löscher W; Erker T; Müller M
Nucl Med Biol; 2010 Jul; 37(5):637-44. PubMed ID: 20610168
[TBL] [Abstract][Full Text] [Related]
40. "Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".
Marchetti S; Pluim D; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
Invest New Drugs; 2014 Dec; 32(6):1083-95. PubMed ID: 25078948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
